how long tesamorelin: Frequently asked questions

Yes. Co-administration of strong CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit juice) reduces Ipamorelin's hepatic metabolism by 30–50%, extending its plasma half-life from 2–3 hours to 3.5–5 hours. This prolongs detectable presence to 36–48 hours and delays complete clearance by an additional 24–48 hours. Research protocols must document all concomitant medications and adjust washout timelines accordingly. Tesamorelin clearance remains unaffected because it's metabolised by peptidases, not cytochrome enzymes.

Yes, but only marginally. Single-week exposure doesn't induce significant hepatic enzyme upregulation or receptor desensitisation, so both peptides follow first-dose clearance kinetics. Tesamorelin clears within 24 hours, Ipamorelin within 48–72 hours, and IGF-1 normalises within 72–96 hours. Total systemic clearance occurs in 4–5 days instead of 7. Researchers conducting acute dosing studies can use a 5-day washout instead of the 7-day standard applied after chronic use.

Significantly. Ipamorelin relies on renal filtration for 60–70% of its elimination. Subjects with estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m² show 40–60% longer urinary excretion times. Extending Ipamorelin detection from 48 hours to 72–96 hours. Tesamorelin clearance is less affected because enzymatic degradation occurs independently of kidney function, but metabolite accumulation can still occur. Protocols involving subjects with chronic kidney disease should extend washout periods to 10–14 days.

Improper storage (temperature excursions above 8°C, exposure to light, contamination) degrades the peptide before injection. Not after. Once injected, clearance kinetics remain identical whether the peptide was stored correctly or not. The difference is potency: degraded tesamorelin produces a smaller GH pulse and lower IGF-1 elevation, but the peptide fragments still clear within the same 2–3 hour window. Always store reconstituted tesamorelin at 2–8°C and use within 28 days.

Verify reconstitution and storage first. Temperature excursions are the most common cause of 'non-response.' If storage was correct, assess dosing consistency (were any doses skipped?) and injection technique (subcutaneous administration in abdominal tissue, not intramuscular). IGF-1 serum testing at week 6 determines whether the peptides are engaging their target receptors. If IGF-1 hasn't risen from baseline, the peptide is either inactive or underdosed. If IGF-1 is elevated but body composition hasn't changed, extend the protocol to 12 weeks before concluding non-response.

Doubling the dose doesn't proportionally accelerate outcomes and significantly increases side effect risk. Tesamorelin doses above 2mg/day elevate cortisol and can cause joint pain, insulin resistance, and fluid retention. Ipamorelin doses above 300mcg/day show diminishing returns due to receptor saturation. The pituitary can only release so much GH per pulse regardless of stimulus intensity. Standard protocols use 2mg Tesamorelin + 200mcg Ipamorelin because that dosing hits the ceiling of the dose-response curve without crossing into adverse event territory.

If a procedure requires no active peptides in circulation, stop tesamorelin 48 hours beforehand. The peptide itself clears in hours, but IGF-1 levels take 48–72 hours to return to baseline. For elective surgery, a 72-hour washout ensures no residual hormonal effects interfere with anaesthesia response or wound healing. Labs measuring baseline IGF-1 or GH should be scheduled at least 96 hours after the last dose.

Tesamorelin does not accumulate. Missing a single dose means the peptide from the prior injection is already fully cleared (within 2–3 hours), and IGF-1 elevation returns to baseline within 48–72 hours. Resume dosing the next evening at the regular time. Do not double-dose. Multi-day gaps reset IGF-1 levels entirely, requiring several days of resumed dosing to re-establish steady-state elevation.

Missing three doses disrupts the cumulative IGF-1 elevation that drives outcomes. Resume dosing immediately at your regular schedule. Do not 'make up' missed doses by doubling or tripling the next injection. The peptides work through sustained pulsatile stimulation, not bolus loading. Missing three doses in a 12-week protocol extends the timeline to measurable outcomes by approximately 10–14 days because the cumulative metabolic shifts reset partially during the gap.

Discard the vial immediately. Tesamorelin and Ipamorelin undergo irreversible aggregation when held at room temperature (20–25°C) for more than two hours. Overnight exposure (8–12 hours) guarantees complete loss of structural integrity. The peptide may still look clear and sterile, but the amino acid chains have clumped into inactive aggregates that no longer bind to ghrelin or GHRH receptors. Using degraded peptide introduces uncontrolled variability into your research and produces unreliable results. There is no method to confirm potency at home, and attempting to 'rescue' the vial by refrigerating it afterward does not reverse the damage.

Use a portable medical cooler with temperature monitoring capability. The vial must remain between 2–8°C during the entire transport window. Standard insulated lunch boxes and ice packs are insufficient because they do not maintain precise temperature control and can cause freezing if the ice pack contacts the vial directly. Purpose-built insulin travel cases like the FRIO wallet use evaporative cooling and maintain 2–8°C for 36–48 hours without electricity or ice. If transport time exceeds 48 hours or external temperature exceeds 30°C, cold chain integrity cannot be guaranteed with passive cooling alone. Consider shipping the unreconstituted lyophilised vial instead and reconstituting it upon arrival.

Discard it. The 28-day stability window is a conservative clinical standard based on the period during which peptides maintain at least 90% of their original potency under ideal conditions. After 28 days, hydrolysis and oxidation have measurably reduced peptide concentration and altered the amino acid sequence in ways that compromise receptor binding. Continuing to use solution beyond this window means you cannot accurately calculate dose or predict biological activity. Your protocol loses experimental validity. If you consistently have significant volume remaining at the 28-day mark, reduce your reconstitution volume or purchase smaller vials matched to your actual usage rate.

This is acceptable if performed under strict sterile technique immediately after reconstitution. Use sterile transfer needles and pre-sterilized glass vials with rubber stoppers. Never reuse empty vials from previous batches. Draw half the reconstituted solution into a sterile syringe, inject it into the second sterile vial, and seal immediately. Label both vials with the reconstitution date and peptide concentration. Both vials are now subject to the same 28-day stability window. Splitting vials reduces the number of needle punctures per stopper, which extends seal integrity and reduces contamination risk for protocols requiring 20+ injections.

Use a medical-grade cooler with reusable ice packs or a thermoelectric cooling case rated for 2–8°C. Standard ice chests with loose ice allow temperatures to drop below 0°C, which freezes the solution and causes ice crystal damage. Insulin travel cases designed for diabetic patients maintain 2–8°C for 12–48 hours depending on ambient temperature and are widely available. Monitor the internal temperature with a digital thermometer throughout transport. If the solution freezes or exceeds 8°C for more than 4 hours, discard it upon arrival rather than guessing at remaining potency.

Discard immediately without injecting. Cloudiness indicates protein aggregation; visible particles suggest either aggregation or microbial contamination. Neither is reversible. Aggregated Tesamorelin cannot bind to GHRH receptors and may trigger immune responses if injected. Particulate contamination introduces infection risk. Clear solution is necessary but not sufficient to confirm potency. Cloudy or particulate solution is definitive evidence of failure. Reconstitute a fresh vial using sterile technique and verify proper refrigeration throughout the storage period.

How long Tesamorelin vial lasts shortens proportionally to time spent above 8°C. A refrigerator that cycles between 4–10°C throughout the day subjects the peptide to cumulative thermal stress. If the average temperature stays below 8°C, expect 30–40% potency loss over a 28-day period compared to stable 4°C storage. Invest in a dedicated laboratory refrigerator with tight temperature control (±1°C variance), or use a secondary thermometer to verify your home refrigerator maintains 2–8°C consistently. Store the vial on a middle shelf toward the back, never in the door.

Contact the supplier immediately. Lyophilised Tesamorelin can tolerate brief ambient temperature exposure (24–48 hours at 20–25°C), but shipping in summer heat. Where package interiors reach 35–45°C in delivery trucks. Denatures the peptide irreversibly. Reputable suppliers like Real Peptides include temperature monitoring strips or data loggers with shipments; check the indicator to confirm the package stayed below 25°C. If the strip shows temperature excursions above 30°C, request a replacement vial. Most suppliers replace heat-damaged shipments at no cost when temperature abuse is documented.

Discard the vial. A reconstituted Tesamorelin solution left at room temperature (20–25°C) for 8–12 hours has crossed the oxidation threshold where methionine residues aggregate into insoluble complexes. Even if the solution appears clear, bioactivity has dropped below therapeutic levels. You cannot reverse peptide denaturation by re-refrigerating the vial. The financial loss from discarding one vial is significantly smaller than the research setback from using degraded peptide and attributing null results to the compound rather than handling error.

Tesamorelin's 26–38 minute half-life means GH pulsatility returns to baseline within hours of a missed dose. Skipping even two consecutive doses resets IGF-1 accumulation, effectively restarting the 7–14 day ramp-up period. Research protocols must build in compliance tracking. Missed doses aren't just noise, they're structural failures that invalidate timeline assumptions. Wearable injection trackers or witnessed dosing schedules are standard in rigorous tesamorelin trials for this reason.

Monitor it with a calibrated thermometer for 48 hours. If the range stays within 2–8°C most of the time with brief excursions to 10°C (less than 2 hours per day), the tesamorelin remains usable for the full 28 days. If the refrigerator consistently runs at 9–10°C, reduce the stability window to 21 days and consider upgrading to a pharmaceutical-grade unit. Tesamorelin stored at 10°C degrades approximately 30% faster than at 4°C. Shortening the window compensates for the elevated baseline temperature.